SUNPHARMA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 3.8

📊 Analysis: SUNPHARMA shows moderate potential for intraday trading today. RSI at 42.8 indicates neutral momentum, while MACD (10.5) is positive, suggesting short-term bullishness. Current price (1,745 ₹) is aligned with DMA 50 (1,746 ₹) and above DMA 200 (1,701 ₹), providing technical support. Strong volume (37,28,300) compared to weekly average (22,09,775) adds conviction for intraday moves.

💡 Optimal Buy Price: 1,735–1,740 ₹ (near support zone).

🎯 Profit Exit Levels: 1,760 ₹ (first resistance), 1,775 ₹ (secondary resistance).

🛡️ Stop-Loss: 1,725 ₹ (below near-term support).

⏱️ If Already Holding: Consider exiting near 1,760–1,775 ₹ if momentum slows. If price breaks below 1,725 ₹ with volume, cut losses immediately.

✅ Positive

• 📈 Strong ROE (17.8%) and ROCE (16.8%) reflect efficient capital use.
• 💰 Dividend yield (0.92%) provides shareholder returns.
• 📊 PEG ratio (1.22) indicates fair valuation relative to growth.
• 📦 High trading volume supports intraday liquidity.

⚠️ Limitation

• 📉 High P/E (89.6) compared to industry average (30.6).
• 🔻 Debt-to-equity (0.56) is higher than peers, adding leverage risk.
• 📊 Quarterly profit variance (-32.7%) shows earnings pressure.

📰 Company Negative News

• ⚠️ Profit contraction (564 Cr. vs 927 Cr. previous quarter).
• 📉 FII holding decreased (-0.71%), signaling reduced foreign investor confidence.

🌟 Company Positive News

• 💡 DII holding increased (0.74%), showing domestic institutional support.
• 🏭 Strong market cap (4,18,684 Cr.) ensures industry leadership.
• 📊 EPS of 18.7 ₹ supports long-term fundamentals.

🏭 Industry

• 📊 Industry PE at 30.6, much lower than SUNPHARMA’s valuation, indicating premium pricing.
• 🌱 Pharma sector demand remains resilient, supported by healthcare growth trends.

📌 Conclusion

SUNPHARMA is a moderate intraday candidate today with strong volume and positive MACD. Traders may attempt entries near 1,735–1,740 ₹ with profit exits at 1,760–1,775 ₹ and stop-loss at 1,725 ₹. Suitable for cautious intraday trades with momentum confirmation.

Would you like me to extend this with a peer benchmarking overlay in the pharma sector so you can compare SUNPHARMA’s intraday strength against competitors like DRREDDY, CIPLA, and DIVISLAB?